U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Go back to U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility| Pfizer Inc. (NYSE: PFE) | Delayed: 27.93 +0.19 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.74 | 52 Week High | $37.39 | |||
| Open | $27.74 | 52 Week Low | $28.25 | |||
| Day High | $28.00 | P/E | 16.93 | |||
| Day Low | $27.49 | EPS | $1.65 | |||
| Volume | 26,668,060 | |||||
